Computational Patient Selection for Extracellular Matrix Therapies: A Machine Learning Framework for Phase II Trial Optimization
Live Interactive Clinical Interface: https://ventrigelcds.streamlit.app/ Abstract: Phase II cardiovascular trials fail frequently because of patient heterogeneity and high capital costs, with only an estimated 25 percent of cardiovascular drugs successfully transitioning to Phase III. Extracellular matrix hydrogels like VentriGel provide structural repair after a myocardial infarction. However, broad clinical inclusion criteria weaken the observed therapeutic effects, which forces trial designers to use massive sample sizes to reach statistical significance. This study introduces an enterprise-grade machine learning Clinical Decision Support tool designed to mathematically optimize patient selection for Phase II clinical trials. Baseline clinical parameters were extracted from published Phase I trial documentation using high-precision coordinate tracking software. To solve the critical bottleneck of small sample sizes, an expanded synthetic cohort of 2000 patient records was engineered using stochastic Monte Carlo simulations governed by a biological covariance penalty index and guideline-directed medical therapy adherence logs. A comprehensive machine learning evaluation arena tested five unique classification algorithms using five-fold stratified cross-validation. The Random Forest Classifier emerged as the champion model, identifying the optimal therapeutic response window with a test Area Under the Curve score of 100 percent, an accuracy of 99.75 percent, and an F1 score of 99.83 percent. The winning pipeline was serialized into a production-ready binary artifact and deployed into an interactive electronic medical record web interface for real-time clinical inference. By narrowing trial inclusion criteria strictly to high probability responders, this computational framework reduces required sample sizes, mitigates algorithmic bias through rigorous data leakage prevention, and lowers the financial barriers preventing advanced cardiovascular biotherapeutics from reaching the commercial market. Extensive mathematical modeling of physiological covariance and risk stratification further ensures that patient safety is preserved across heterogeneous cohorts, paving the way for next-generation clinical trial architectures. Comprehensive validation protocols, multi-tier auditing systems, and detailed electronic medical record integration methodologies further reinforce the operational robustness of the presented software architecture.